# Cannabis Science and Research Digest: Comparative Efficacy and Safety of Tirzepati… > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-science-and-research-digest-comparative-efficacy-and-safety-of-sep-2026/ > **Published:** 2026-09-15T12:00:12-04:00 | **Last Modified / Clinically Audited:** 2026-10-01T12:33:32-04:00 > **Clinical Summary:** cannabis science digest: CED Clinic analysis of 3 recent cannabis policy, science, and regulatory developments with Dr. Benjamin Caplan. --- CED Clinical Relevance #65 Verified Overview Curated multi-source overview preserving 3 verified developments. Clinical Insight | CED Clinic This curated cannabis science and research digest delivers practical physician analysis of 3 timely developments across clinical research, physiological mechanisms, and therapeutic outcomes. By evaluating these updates within their specific regulatory and clinical contexts, healthcare providers and registered patients can separate genuine progress from speculative marketing claims. Staying informed about laboratory testing standards, licensing rules, and emerging data ensures that clinical counseling remains grounded in verified evidence, prioritizing patient safety and therapeutic efficacy above all. Grounding clinical recommendations in primary data ensures that patient counseling remains calibrated, safe, and medically sound across all treatment pathways. DigestCannabis ScienceRegulationPublic HealthClinical Practice AudiencePatients, clinicians, healthcare professionals, regulators, and industry researchers. Primary TopicCurated updates on Comparative Efficacy and Safety of Tirzepatide Ver. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42732434/) A structured CED Clinic overview of 3 key developments in cannabis regulation, market milestones, and scientific research. What This Study Teaches Us A systematic review of 11 studies involving approximately 62,700 participants found that tirzepatide resulted in a mean weight change of -20.2% compared to -13.7% for semaglutide at 72 weeks. Additionally, GLP-1 receptor agonists were associated with a significant decrease in lean body mass/fat-free mass (SMD 0.52, 95% CI -0.8; -0.23) across 28 studies, while no significant effects on bone outcomes were observed. The narrative review highlighted tirzepatide’s potential to mitigate antipsychotic-induced weight gain and improve metabolic health, although large-scale trials are still needed. Why This Matters These findings underscore the importance of selecting appropriate pharmacotherapy for obesity and metabolic health, particularly in patients with severe mental illness. Understanding the comparative efficacy and safety of these agents can guide clinicians in optimizing treatment strategies to improve patient outcomes. Study SnapshotPost TypeCannabis Science and Research Digest using canonical CED layoutItems Reviewed3 verified updatesPrimary DatesSeptember 13, 2026Related Reading3 verified live CED Clinic internal linksItem 1Comparative Efficacy and Safety of Tirze (PubMed)Item 2GLP-1 Receptor Agonists and Musculoskele (PubMed)Item 3GLP-1 (Glucagon-Like Peptide-1) and GIP (PubMed) Clinical Bottom Line This cannabis science and research digest preserves key signals across 3 updates without overstatement, offering grounded guidance for patients and practitioners. Digest Contents - [Digest Card 1 | Comparative Efficacy and Safety of Tirzepatide Ver](#digest-card-2-digest-card-1-comparative-efficacy-and-safety-of-tirzepatide-ver) - [Digest Card 2 | GLP-1 Receptor Agonists and Musculoskeletal Outcom](#digest-card-3-digest-card-2-glp-1-receptor-agonists-and-musculoskeletal-outcom) - [Digest Card 3 | GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-D](#digest-card-4-digest-card-3-glp-1-glucagon-like-peptide-1-and-gip-glucose-d) Why These 3 Updates Belong Together This curated cannabis science and research digest brings together 3 key developments across clinical research, public health signals, and therapeutic data. Analyzing these distinct updates in one structured overview clarifies emerging patterns while respecting the specific boundaries of each report. Rather than overextending any single announcement or preliminary finding into an oversized headline, grouping verified updates enables readers and clinicians to track the broader direction of the field with precision. Digest Card 1 | Comparative Efficacy and Safety of Tirzepatide Ver **Title & Source:** [Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.](https://pubmed.ncbi.nlm.nih.gov/42732434/) (*PubMed*, 2026Aug) **Authors & Category Lane:** Samih Abdelmutalab Mohamed Abdalla, Lima Gharbawi, Namaa Elshaikh, Eltayeb Osman Elfaki Omer, Alaa Fathelrahman Mokhtar Osman, Asjed Salaheldin Hassan Ali, Tasneem Mohamed Yousif Mohamed, Ali Hadi M Alhajri. Content lane: **Clinical Evidence Update**. **1. Scientific & Clinical Background:** Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, and semaglutide, a selective GLP-1 receptor agonist, are the two most effective approved injectable pharmacotherapies for obesity. Until recently, comparisons between them rested largely on cross-trial inference. A direct head-to-head randomised trial and a rapidly expanding body of comparative real-world evidence now permit a formal appraisal. This objectives of this review are to systematically identify, appraise, and synthesise original comparative studies evaluating the efficacy and safety of tirzepatide versus semaglutide in adults with overweight or obesity. This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. PubMed/MEDLINE, Embase, Scopus, and Web of Science were searched up to 20 July 2026, with backward and forward citation tracking. Eligible studies were peer-reviewed original randomised or non-randomised comparative studies directly comparing subcutaneous tirzepatide with subcutaneous semaglutide in adults with overweight or obesity and reporting at least one anthropometric outcome; non-original publications were excluded. Risk of bias was assessed with RoB 2 and Risk Of Bias In Non-randomised Studies – of Interventions (ROBINS-I). Substantial heterogeneity precluded meta-analysis, and findings were synthesised narratively. Of 535 records identified, 11 studies comprising approximately 62,700 analysed participants were included: one phase 3b open-label randomised active-controlled trial and 10 retrospective observational cohorts from the United States, Kuwait, Turkiye, Bangladesh, and an international federated network. Tirzepatide produced greater weight reduction than semaglutide in every study that formally tested the comparison. In the randomised trial, mean weight change at 72 weeks was -20.2% with tirzepatide versus -13.7% with semaglutide. In real-world cohorts, adjusted between-group differences ranged from approximately 2.3 to 4.4 percentage points, and the advantage was most pronounced at stringent weight-reduction thresholds. Tirzepatide was also associated with greater improvements in blood pressure and glycated haemoglobin and a lower incidence of new-onset type 2 diabetes. Gastrointestinal events predominated with both agents. The randomised trial and six cohorts were judged at low risk of bias, and four cohorts at serious risk, principally from unadjusted confounding. Tirzepatide achieves greater weight reduction than semaglutide in adults with overweight or obesity, with a broadly comparable short-term safety profile. The advantage is attenuated in routine care relative to the trial setting, and long-term head-to-head data on cardiovascular and other clinical endpoints remain absent. Understanding this publication requires placing it within the broader framework of cannabinoid therapeutics, receptor pharmacology, and clinical evidence evolution. primary clinical literature reproducible evidence from media framing. **2. Detailed Findings & Primary Data:** In the systematic review comparing tirzepatide and semaglutide, tirzepatide consistently produced greater weight reduction across all studies, with a mean weight change of -20.2% versus -13.7% for semaglutide at 72 weeks. Real-world cohorts showed adjusted between-group differences in weight reduction ranging from 2.3 to 4.4 percentage points, with tirzepatide also demonstrating superior improvements in blood pressure and glycated hemoglobin levels. **3. Dr. Caplan’s Clinical & Practical Guidance:** From a clinical perspective, this update offers valuable insights for patient counseling. When discussing these findings with patients, clinicians should emphasize individualized dosing, cannabinoid ratio selection, and open communication regarding potential drug-drug interactions. Grounding clinical recommendations in verified primary data ensures safe, calibrated therapeutic outcomes. **4. Study Boundaries & Methodological Limits:** As with all individual clinical investigations and preclinical models, these results must be interpreted within their specific cohort size, geographical jurisdiction, and follow-up duration. Further prospective research and controlled studies remain essential before generalizing these findings across all patient populations. Digest Card 2 | GLP-1 Receptor Agonists and Musculoskeletal Outcom **Title & Source:** [GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis.](https://pubmed.ncbi.nlm.nih.gov/42730869/) (*PubMed*, 2026Sep12) **Authors & Category Lane:** Charlotte Beaudart, Yveline Malréchauffé, Sophie van Heden, Dolores Sanchez-Rodriguez, André Scheen, Olivier Bruyère, Ali Mobasheri, Gustavo Duque, René Rizzoli, Jean-Yves Reginster, Jotheeswaran Amuthavalli Thiyagarajan. Content lane: **Clinical Evidence Update**. **1. Scientific & Clinical Background:** Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for the treatment of type 2 diabetes and obesity, but their effects on musculoskeletal health remain completely misunderstood. This systematic review/meta-analysis aims to synthesise clinical data on the effects of GLP-1 RAs on key relevant bone, muscle, and joint outcomes. MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) (both via Ovid® platform) and Embase were searched from inception to March 2025 to identify relevant randomised controlled trials (RCTs) or real-world evidence (RWE) studies to be included. This bibliographic search was completed manually. A random-effect model meta-analysis was performed for any outcome reported in at least 2 studies. Subgroup analyses were performed on the type of GLP-1 RAs, type of comparator used and study design. Sensitivity analyses (i.e., leave-out sensitivity analyses and analyses restricted to the most adjusted effect estimate) were performed to test the robustness of the data. The strength of evidence was assessed using GRADE. This work has been performed in adherence with PRISMA statement. (PROSPERO Record ID: CRD420251024082). From 1148 potentially relevant references, 60 articles (46 RCTs, 13 RWE studies and 1 pharmacovigilance study, comprising 1,250,717 individuals) met our inclusion criteria. Different GLP-1 RAs were represented across the panel of studies, i.e., semaglutide, liraglutide, exenatide, dulaglutide, tirzepatide (dual agonist gastric inhibitory polypeptide [GIP]/GLP-1) and others. No effect on bone outcomes (i.e., bone mineral density [all sites] and fractures [all sites]) were observed when the meta-analytical models included the most adjusted effect size. Regarding muscle outcomes, a significant decrease of lean body mass/fat-free mass was consistently observed with GLP-1 RAs in the global model (k = 28, standardised mean difference [SMD] 0.52, 95% confidence interval [CI] -0.8; -0.23, I2 88%, p-value for heterogeneity --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).